The autism treatment network and autism intervention research network on physical health: Future directions

Pediatrics

Volumn 130, Issue SUPPL. 2, 2012, Pages

  Perrin, James M ^a   Coury, Daniel L ^b   Jones, Nancy ^c   Lajonchere, Clara ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Autism Speaks Inc   (United States)

Author keywords

Autism spectrum disorder

Indexed keywords

ARTICLE; AUTISM; AUTISM INTERVENTION RESEARCH NETWORK; AUTISM INTERVENTION RESEARCH NETWORK ON PHYSICAL HEALTH; AUTISM TREATMENT NETWORK; CHILD HEALTH; COMORBIDITY; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; GASTROINTESTINAL DISEASE; HEALTH CARE ORGANIZATION; HUMAN; METABOLIC DISORDER; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REGISTER; SEIZURE; SLEEP DISORDER;

EID: 84868630017     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0900S     Document Type: Article

References (12)

1. Abrahams BS, Geschwind DH. Connecting genes to brain in the autism spectrum disorders. Arch Neurol. 2010;67(4):395-399
2. Stein REK, Perrin JM, Iezzoni LI. Health care: access and medical support for youth and young adults with chronic health conditions and disabilities. In: Lollar D, ed. Launching into Adulthood. Baltimore, MD: Paul H Brookes Publishing; 2010:77-102
3. Seltzer MM, Floyd F, Song J, Greenberg J, Hong J. Midlife and aging parents of adults with intellectual and developmental disabilities: impacts of lifelong parenting. Am J Intellect Dev Disabil . 2011;116(6):479-499
4. Lit L, Sharp FR, Bertoglio K, et al. Gene expression in blood is associated with risperidone response in children with autism spectrum disorders [published online ahead of print June 7, 2011]. Pharmacogenomics J. doi:10.1038/tpj.2011.23
5. Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010;10(5):418-430
6. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764
7. Shen Y, Dies KA, Holm IA, et al Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics. 2010;125(4). Available at: www.pediatrics.org/ cgi/content/full/125/4/e727
8. McGrew SG, Peters BR, Crittendon JA, Veenstra-Vanderweele J. Diagnostic yield of chromosomal microarray analysis in an autism primary care practice: which guidelines to implement? J Autism Dev Disord . 2012;42(8):1582-1591
9. Owley T, Brune CW, Salt J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010;3(1):1-7
10. Perrin JM. How can quality improvement enhance the lives of children with disabilities? Future Child. 2012;22(1):149-168
11. Patient-Centered Outcomes Research. Available at: www.pcori.org/patient- centered-outcomes-research/. Accessed March 2, 2012.
12. American Academy of Pediatrics. Report of the Task Force on Mental Health. Pediatrics. 2010; 125(suppl 3):S69-S125